niacinamide has been researched along with Hypertension, Portal in 10 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Hypertension, Portal: Abnormal increase of resistance to blood flow within the hepatic PORTAL SYSTEM, frequently seen in LIVER CIRRHOSIS and conditions with obstruction of the PORTAL VEIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with liver fibrosis/cirrhosis and hepatocellular carcinoma were treated with sorafenib 400 mg b." | 7.78 | The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma--a pilot study. ( Ferlitsch, A; Peck-Radosavljevic, M; Pinter, M; Reiberger, T; Rohr-Udilova, N; Sieghart, W, 2012) |
| " As the multikinase inhibitor sorafenib inhibits ERK, we tested the effect of sorafenib on haemodynamics and dysregulated vascular Rho kinase in rats with secondary biliary cirrhosis." | 7.75 | Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis. ( Heller, J; Hennenberg, M; Kohistani, AZ; Sauerbruch, T; Stark, C; Trebicka, J, 2009) |
| " This leads to the decrease in intrahepatic vascular resistance, but also to liver damage in the dosage we used." | 5.37 | Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis. ( Fischer, HP; Granzow, M; Heller, J; Hennenberg, M; Klein, S; Kohistani, Z; Körner, C; Krämer, B; Nischalke, HD; Sauerbruch, T; Stark, C; Trebicka, J, 2011) |
| " Sorafenib, a tyrosine kinase inhibitor is validated in advanced hepatocellular carcinoma." | 5.15 | Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib. ( Blanchet, B; Chaussade, S; Coriat, R; Goldwasser, F; Gouya, H; Legmann, P; Mir, O; Pol, S; Ropert, S; Sogni, P; Vignaux, O, 2011) |
| "Patients with liver fibrosis/cirrhosis and hepatocellular carcinoma were treated with sorafenib 400 mg b." | 3.78 | The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma--a pilot study. ( Ferlitsch, A; Peck-Radosavljevic, M; Pinter, M; Reiberger, T; Rohr-Udilova, N; Sieghart, W, 2012) |
| " As the multikinase inhibitor sorafenib inhibits ERK, we tested the effect of sorafenib on haemodynamics and dysregulated vascular Rho kinase in rats with secondary biliary cirrhosis." | 3.75 | Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis. ( Heller, J; Hennenberg, M; Kohistani, AZ; Sauerbruch, T; Stark, C; Trebicka, J, 2009) |
| "Sorafenib is an oral tyrosine kinase inhibitor that has been shown to significantly improve blood flow dynamics, inhibit angiogenesis, reduce liver fibrosis and decrease portal pressure in the treatment of portal hypertension." | 2.50 | [Therapeutic effect of sorafenib on portal hypertension: research progress and mechanisms]. ( Cheng, Y; Li, A; Luo, R; Zhu, Y, 2014) |
| " This leads to the decrease in intrahepatic vascular resistance, but also to liver damage in the dosage we used." | 1.37 | Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis. ( Fischer, HP; Granzow, M; Heller, J; Hennenberg, M; Klein, S; Kohistani, Z; Körner, C; Krämer, B; Nischalke, HD; Sauerbruch, T; Stark, C; Trebicka, J, 2011) |
| "Treatment with sorafenib resulted in a significant decrease of PP (p<0." | 1.35 | Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. ( Angermayr, B; Gangl, A; Mitterhauser, M; Peck-Radosavljevic, M; Reiberger, T; Rohr-Udilova, N; Schwabl, P, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhu, Y | 1 |
| Cheng, Y | 1 |
| Li, A | 1 |
| Luo, R | 1 |
| Mejias, M | 2 |
| Garcia-Pras, E | 2 |
| Tiani, C | 1 |
| Miquel, R | 1 |
| Bosch, J | 2 |
| Fernandez, M | 2 |
| Shah, VH | 1 |
| Bruix, J | 1 |
| Hennenberg, M | 2 |
| Trebicka, J | 2 |
| Stark, C | 2 |
| Kohistani, AZ | 1 |
| Heller, J | 2 |
| Sauerbruch, T | 2 |
| Reiberger, T | 2 |
| Angermayr, B | 1 |
| Schwabl, P | 1 |
| Rohr-Udilova, N | 2 |
| Mitterhauser, M | 1 |
| Gangl, A | 1 |
| Peck-Radosavljevic, M | 2 |
| Kohistani, Z | 1 |
| Nischalke, HD | 1 |
| Krämer, B | 1 |
| Körner, C | 1 |
| Klein, S | 1 |
| Granzow, M | 1 |
| Fischer, HP | 1 |
| Coriat, R | 1 |
| Gouya, H | 1 |
| Mir, O | 1 |
| Ropert, S | 1 |
| Vignaux, O | 1 |
| Chaussade, S | 1 |
| Sogni, P | 1 |
| Pol, S | 1 |
| Blanchet, B | 1 |
| Legmann, P | 1 |
| Goldwasser, F | 1 |
| Pinter, M | 1 |
| Sieghart, W | 1 |
| Ferlitsch, A | 1 |
| D'Amico, M | 1 |
| Abraldes, JG | 1 |
| García-Pagán, JC | 1 |
| Hsu, SJ | 1 |
| Hsin, IF | 1 |
| Lin, YL | 1 |
| Chen, YC | 1 |
| Huang, HC | 1 |
| Lee, FY | 1 |
| Lin, HC | 1 |
| Chang, CC | 1 |
| Lee, SD | 1 |
1 review available for niacinamide and Hypertension, Portal
| Article | Year |
|---|---|
[Therapeutic effect of sorafenib on portal hypertension: research progress and mechanisms].
Topics: Animals; Humans; Hypertension, Portal; Niacinamide; Phenylurea Compounds; Sorafenib | 2014 |
1 trial available for niacinamide and Hypertension, Portal
| Article | Year |
|---|---|
Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progressio | 2011 |
8 other studies available for niacinamide and Hypertension, Portal
| Article | Year |
|---|---|
Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats.
Topics: Animals; Benzenesulfonates; Collateral Circulation; Enteritis; Heme Oxygenase-1; Hepatitis; Hyperten | 2009 |
Antiangiogenic therapy: not just for cancer anymore?
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Humans; Hypertension, Po | 2009 |
Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis.
Topics: Animals; Aorta; Benzenesulfonates; Blotting, Western; Hypertension, Portal; Liver; Liver Cirrhosis, | 2009 |
Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats.
Topics: Angiogenesis Inhibitors; Animals; Benzenesulfonates; Cell Proliferation; Cytokines; Down-Regulation; | 2009 |
Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis.
Topics: Actins; Animals; Apoptosis; Benzenesulfonates; Caspase 3; Colorimetry; DNA Fragmentation; Hepatic St | 2011 |
The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma--a pilot study.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Hypertension, Portal; Liver Cirr | 2012 |
Effects of the combined administration of propranolol plus sorafenib on portal hypertension in cirrhotic rats.
Topics: Animals; Antihypertensive Agents; Benzenesulfonates; Drug Therapy, Combination; Hypertension, Portal | 2012 |
The influence of sorafenib on hepatic encephalopathy and the mechanistic survey in cirrhotic rats.
Topics: Animals; Disease Models, Animal; Hepatic Encephalopathy; Humans; Hypertension, Portal; Liver Cirrhos | 2012 |